Blog
RSS FeedPosted by Michael Wonder on 08 Jun 2017
Burtomab receives breakthrough therapy designation for advanced form of paediatric cancer
7 June 2017 - Burtomab, a drug for metastatic neuroblastoma, has been granted breakthrough therapy designation by the FDA for the ...
Posted by Michael Wonder on 08 Jun 2017
Cancer drug prices are so high that doctors will test cutting doses
8 June 2017 - A group of prominent cancer doctors is planning a novel assault on high drug costs, using ...
Posted by Michael Wonder on 08 Jun 2017
Novartis’s next challenge: pricing breakthrough cancer treatment
8 June 2017 - Swiss drugmaker mulls linking cost to results in each patient. ...
Posted by Michael Wonder on 08 Jun 2017
Institute for Clinical and Economic Review's final report on treatments for atopic dermatitis provides policy recommendations to support appropriate patient access to dupilumab
8 June 2017 - Report analyses evidence on the comparative effectiveness of dupilumab, finds price well-aligned with added value for patients; ...
Posted by Michael Wonder on 08 Jun 2017
FDA requests removal of Opana ER for risks related to abuse
8 June 2017 - Today, the U.S. FDA requested that Endo Pharmaceuticals remove its opioid pain medication, reformulated Opana ER ...
Posted by Michael Wonder on 08 Jun 2017
Senate health bill may alienate G.O.P. Conservatives
7 May 2017 - Senate Republicans are closing in on a bill to repeal President Barack Obama’s signature health care ...
Posted by Michael Wonder on 08 Jun 2017
Bristol-Myers Squibb announces availability of new Orencia (abatacept) subcutaneous administration option for patients 2 years of age and older with moderately to severely active polyarticular juvenile idiopathic arthritis
8 June 2017 - New pre-filled syringe option can be administered at home. ...
Posted by Michael Wonder on 08 Jun 2017
Major flaws in US drugs with 'accelerated' approval, research suggests
7 June 2017 - A new study published today has exposed major flaws in the fast tracking of some drugs ...
Posted by Michael Wonder on 08 Jun 2017
Biosimilar drugs offer promise for drug price savings, but risks remain
5 June 2017 - The issue of prescription drug prices continues to top the list of public concerns about health ...
Posted by Michael Wonder on 08 Jun 2017
FDA expands approved use of Opdivo to treat lung cancer
4 March 2015 - The U.S. Food and Drug Administration today expanded the approved use of Opdivo (nivolumab) to treat ...
Posted by Michael Wonder on 08 Jun 2017
Bristol-Myers Squibb receives approval from the US FDA for the Opdivo (nivolumab) + Yervoy (ipilimumab) regimen in BRAF V600 wild-type unresectable or metastatic melanoma
30 September 2015 - First and only FDA approved combination of two immuno-oncology agents. ...
Posted by Michael Wonder on 08 Jun 2017
Novartis receives two new FDA approvals for Cosentyx to treat patients with ankylosing spondylitis and psoriatic arthritis in the US
15 January 2016 - FDA approval for Cosentyx is based on efficacy and safety outcomes shown across four Phase III studies, ...
Posted by Michael Wonder on 08 Jun 2017
Mateon Therapeutics receives FDA fast track designation for OXI4503 in patients with acute myeloid leukaemia
7 June 2017 - Mateon Therapeutics today announced that the U.S. FDA has granted fast track designation to the company's product ...
Posted by Michael Wonder on 07 Jun 2017
Calithera Biosciences announces FDA fast track designation granted to CB-839 for treatment of patients with renal cell carcinoma
Calithera Biosciences today announced that the U.S. FDA has granted fast track designation to CB-839 in combination with everolimus, for ...
Posted by Michael Wonder on 07 Jun 2017
Senate GOP aiming to conclude divisive health-care push — one way or the other
6 June 2017 - Senate Republican leaders on Tuesday unveiled a series of policy options to overhaul the nation’s health-care ...